home · filing · 0001628280-22-004490
8-K filed March 1, 2022, 6:59 PM ET
ticker NGNE
CIK 0001404644
earnings
confidence high
sentiment negative
materiality 0.70
Neoleukin reports 2021 net loss of $60.7M, cash $142.5M; NL-201 interim data expected H2 2022
Neurogene Inc.
2021-FY EPS reported
-$1.10
Net loss $60.7M in 2021 vs $33.3M in 2020; cash & equivalents $142.5M down from $192.6M; runway into H2 2023.
Phase 1 interim data for NL-201 in solid tumors expected H2 2022; combination trial with pembrolizumab planned.
R&D expenses $39.2M (up 61%), G&A $21.5M (up 25%) driven by clinical activities and personnel costs.
Rohan Palekar (CEO of 89bio) appointed to board; Lewis Williams resigns; Drachman named PFO, Smith named PAO.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Lewis T. Williams
Director
Effective 2022-03-02
Successor Rohan Palekar
Filed March 1, 2022, 6:59 PM ET
the Board accepted the resignation of Lewis T. “Rusty” Williams as a member of the Board and its committees, effective as of the Effective Date.
Appointed
Rohan Palekar
Director
Effective 2022-03-02
Filed March 1, 2022, 6:59 PM ET
the Board appointed Rohan Palekar as a Class III director
Effective 2022-03-02
Filed March 1, 2022, 6:59 PM ET
the Board appointed Sean Smith, the Company’s VP, Finance and Controller, as the Company’s Principal Accounting Officer, effective on the Appointment Date.
Effective 2022-03-02
Filed March 1, 2022, 6:59 PM ET
the Board appointed Jonathan Drachman, the Company’s Chief Executive Officer, as the Company’s Principal Financial Officer, effective on March 2, 2022
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Lewis T. Williams resigned as Director at Neurogene Inc..
Action resigned
Role Director
Exact text from the filing
the Board accepted the resignation of Lewis T. “Rusty” Williams as a member of the Board and its committees, effective as of the Effective Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Rohan Palekar was appointed as Director at Neurogene Inc..
Action appointed
Role Director
Exact text from the filing
the Board appointed Rohan Palekar as a Class III director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Sean Smith was appointed as Principal Accounting Officer at Neurogene Inc..
Action appointed
Role Principal Accounting Officer
Exact text from the filing
the Board appointed Sean Smith, the Company’s VP, Finance and Controller, as the Company’s Principal Accounting Officer, effective on the Appointment Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jonathan Drachman was appointed as Principal Financial Officer at Neurogene Inc..
Action appointed
Role Principal Financial Officer
Exact text from the filing
the Board appointed Jonathan Drachman, the Company’s Chief Executive Officer, as the Company’s Principal Financial Officer, effective on March 2, 2022
View on SEC.gov
Source: SEC EDGAR
accession 0001628280-22-004490
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.